STF1 Antibody

What is STF1 and what cellular functions does it regulate?

STF1 (Steroidogenic Transcription Factor 1), also known as NR5A1, is a nuclear receptor that plays an instrumental role in directing the transcriptional control of steroidogenesis. It was initially identified as a tissue-specific transcriptional regulator of cytochrome P450 steroid hydroxylases. Research with knockout mice has demonstrated that STF-1 is required for the development of adrenal glands, gonads, ventromedial hypothalamus, and for the proper functioning of pituitary gonadotropes . In humans, mutations rendering STF-1 transcriptionally inactive can present with testicular failure, ovarian failure, and adrenal insufficiency. Additionally, STF1 has been linked to diseases such as endometriosis and adrenocortical carcinoma .

What are the main applications of STF1 antibodies in research?

STF1 antibodies are primarily used in:

• Western blotting for protein detection and quantification

• Immunohistochemistry for tissue localization studies

• Fluorescence Activated Cell Sorting (FACS) analysis

• Intracellular signaling pathway studies

• Two-hybrid antibody micropattern assays for protein-protein interaction studies

The antibodies are particularly valuable for studying transcription factor dynamics in steroidogenic tissues and for investigating developmental biology questions related to adrenal and gonadal development .

What is the difference between monoclonal and polyclonal STF1 antibodies in experimental applications?

As demonstrated in research findings, monoclonal antibodies like F6A11 have proven superior for FACS applications compared to polyclonal antisera, which were unable to detect shifts in fluorescence even when clear nuclear STF1 staining was visible in immunocytochemistry .

How can I validate the specificity of STF1 antibodies for experimental use?

To validate STF1 antibody specificity, implement these methodological steps:

• Western blot validation: Test the antibody against known positive controls (e.g., nuclear extracts from cell lines that express STF1) and negative controls (cell lines that don't express STF1). For example, antibodies F6A11 and F109-D12 specifically detected a 39 kDa band corresponding to Pdx1/STF1 in nuclear extracts from βTC6 cells but not from αTC1.9 cells .

• Pre-absorption studies: Pre-incubate the antibody with the purified antigen protein (e.g., GST-STF1 fusion protein) before use. The specific binding should be abolished in western blots or immunostaining .

• Cross-reactivity assessment: Test against closely related proteins to ensure specificity.

• Immunohistochemistry patterns: Compare staining patterns with established results from other validated antibodies or with in situ hybridization data.

• Knockout/knockdown controls: If available, test the antibody in tissues or cells where STF1 has been knocked out or knocked down through genetic approaches.

What fixation and sample preparation protocols are optimal for STF1 antibody applications in immunohistochemistry?

For optimal STF1 detection in immunohistochemistry:

• Tissue fixation: 4% paraformaldehyde (PFA) overnight is recommended for maintaining structural integrity while preserving antigenicity.

• Cryoprotection: After fixation, incubate tissue in 30% sucrose overnight before embedding in Tissue-Tek .

• Sectioning: Prepare 10 μm sections and store at -80°C until use.

• Antigen retrieval: This critical step significantly improves signal-to-noise ratio. Use citrate buffer (0.01M, pH 6.0) and microwave heating: 4 minutes at 600W, followed by 15 minutes at 250W, then 20 minutes cooling .

• Blocking: Pre-treatment with 3% H₂O₂ followed by blocking with 10% serum (typically donkey or goat) reduces non-specific binding.

• Antibody incubation: Optimal dilution should be determined empirically, but for monoclonal antibodies like F6A11, 5.00 μg/mL has proven effective .

How can I optimize STF1 antibody protocols for FACS analysis of intracellular proteins?

For successful intracellular FACS analysis using STF1 antibodies:

• Cell fixation: Fix approximately 10⁶ cells using 4% PFA to maintain cellular structure while allowing antibody penetration.

• Permeabilization: Treat cells with 0.03% Triton X-100 in PBS (without Ca²⁺/Mg²⁺) supplemented with 0.1% BSA for one hour to allow antibody access to intracellular antigens .

• Blocking: Add 10% donkey serum for an additional hour to reduce non-specific binding.

• Primary antibody incubation: Incubate overnight with monoclonal anti-STF1 antibody (e.g., F6A11) at 5.00 μg/mL. Include appropriate isotype controls (e.g., mouse IgG1κ) .

• Secondary antibody: After washing three times, incubate with fluorophore-conjugated secondary antibody (e.g., Cy2-conjugated donkey anti-mouse) at 1:300 dilution for one hour .

• Analysis: Analyze on a flow cytometer with appropriate laser and filter settings.

Research has demonstrated that monoclonal antibodies are significantly more effective than polyclonal antisera for intracellular FACS applications. For example, the F6A11 monoclonal antibody detected a 2.3-fold increase in fluorescence intensity after 24 hours of Dox induction in an experimental system, while polyclonal antisera failed to detect any shift in fluorescence .

How can antibody micropatterns be used to study STF1-related protein-protein interactions?

Antibody micropattern technology represents an advanced approach for studying protein-protein interactions involving STF1 or related proteins. The methodology involves:

• Pattern preparation: Generate silicon master molds through semiconductor photolithography. Prepare PDMS stamps using basic elastomer and curing agent (typically in 10:1 ratio) .

• Antibody printing: Ink the stamps with antibody solutions (anti-tag or conformation-specific antibodies) and place them on round microscopy glass coverslips to create micropatterns .

• Cell seeding: Seed approximately 50,000 cells per well onto the antibody patterns and incubate at appropriate temperatures (e.g., 37°C for adhesion, then shift to 25°C overnight for certain applications) .

• Two-hybrid design: For protein interaction studies, utilize a system where one protein construct has a tag recognized by the patterned antibody (e.g., HA tag) while the potential interaction partner carries a fluorescent tag (e.g., GFP). The fluorescent signal will arrange in the pattern shape only if protein-protein interaction occurs .

• Quantification: Calculate the ratio of fluorescence intensity on pattern elements over total fluorescence intensity. Background signals typically show a ratio of approximately 1.1, while positive interactions yield ratios of 1.3 or higher .

This technique has revealed that certain protein interactions (such as MHC-I free heavy chains) occur only under specific conformational conditions, providing insights impossible to obtain through conventional methods .

What are the advantages of using STF1 antibodies for studying feedback regulation mechanisms in transcription factors?

STF1 antibodies offer unique advantages for investigating feedback regulation:

• Quantitative assessment of protein levels: Monoclonal STF1 antibodies enable precise quantification of protein levels via FACS analysis, allowing researchers to track dynamic changes in transcription factor abundance following experimental perturbations .

• Temporal resolution: The ability to follow protein level changes over time with high sensitivity provides insights into regulatory kinetics. For example, research using the F6A11 monoclonal antibody demonstrated a fast and significant rise in mean fluorescence intensity of a transcription factor (2.3-fold increase) after 24 hours of induction, followed by a 3.4-fold reduction 24 hours after removal of the inducing agent .

• Subcellular localization: By combining FACS with fluorescence microscopy, researchers can correlate quantitative changes with subcellular localization, revealing translocation events that may be part of feedback mechanisms .

• Identification of novel feedback loops: The high sensitivity of monoclonal antibodies has enabled discovery of previously unknown negative feedback mechanisms. In one study, induction of exogenous transcription factor led to a reduction in endogenous levels, suggesting a negative feedback loop involved in maintaining correct cellular levels .

• Correlation with functional readouts: By combining antibody-based detection with functional assays, researchers can establish causative relationships in regulatory networks.

How can STF1 antibodies be used to investigate the relationship between neurological syndromes and gastrointestinal disorders?

Recent research has uncovered unexpected connections between neurological conditions and gastrointestinal disorders that can be investigated using antibody-based approaches:

• Detection of cross-reactive antibodies: Anti-neural antibodies like anti-SOX-1 (which shares research contexts with STF1) have been found in patients with both neurological symptoms and gastrointestinal disorders such as Crohn's Disease (CD) .

• Methodological approach:

  • Collect serum samples from patients with established gastrointestinal disorders

  • Screen for the presence of anti-neuronal antibodies using immunoblotting, immunohistochemistry, and cell-based assays

  • Correlate antibody presence with neurological symptoms

  • Perform longitudinal studies to determine if antibody presence predicts neurological complications

• Diagnostic applications: The identification of these antibodies may expand diagnostic workups. As noted in research findings: "As of now, testing for antineuronal antibodies is not included in the diagnostic workup of gastroenterological disorders, which may lead... to overlooking incident neurologic autoimmune diseases in patients with CD" .

• Research implications: This approach may reveal new roles for neural antibodies beyond their known functions as indicators of malignancy, suggesting that "neurological syndromes associated with such autoantibodies may complicate also chronic GI diseases" .

How can I address inconsistent STF1 antibody staining patterns in immunohistochemistry?

Inconsistent staining can significantly impact research outcomes. Address these issues methodically:

• Fixation optimization: Test different fixation protocols, as overfixation can mask epitopes while underfixation can lead to tissue degradation.

• Antigen retrieval evaluation: Compare different antigen retrieval methods:

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0)

  • Heat-induced epitope retrieval using EDTA buffer (pH 8.0)

  • Enzymatic retrieval using proteinase K

• Antibody titration: Perform a systematic titration series (e.g., 1:100, 1:500, 1:1000, 1:5000) to identify the optimal concentration that maximizes specific signal while minimizing background.

• Blocking optimization: Test different blocking solutions including:

  • Normal serum (5-10%) from the species of the secondary antibody

  • Bovine serum albumin (1-5%)

  • Commercial blocking reagents

• Controls for validation: Always include these critical controls:

  • Positive tissue control (known STF1-expressing tissue)

  • Negative tissue control (tissue known not to express STF1)

  • Secondary antibody-only control to assess non-specific binding

  • Isotype control to evaluate background from primary antibody

What approaches can resolve discrepancies between Western blot and immunohistochemistry results when using STF1 antibodies?

Discrepancies between techniques require systematic investigation:

• Epitope accessibility differences: In Western blots, proteins are denatured, exposing all epitopes, while in immunohistochemistry, protein conformation may mask certain epitopes.

  • Solution: Try different fixation and antigen retrieval methods for immunohistochemistry or consider using a different antibody that recognizes a different epitope.

• Protein modifications: Post-translational modifications may differ between sample preparation methods.

  • Solution: Use modification-specific antibodies or perform treatments to remove specific modifications (e.g., phosphatases for phosphorylation).

• Antibody specificity: Some antibodies may recognize cross-reactive proteins in one technique but not the other.

  • Solution: Validate specificity using knockout/knockdown controls in both techniques.

• Antibody concentration optimization: Each technique may require different optimal antibody concentrations.

  • Solution: Perform independent titrations for each technique.

• Validation approach: When discrepancies persist, combine multiple detection methods:

  • RNA analysis (RT-PCR or in situ hybridization)

  • Mass spectrometry for protein identification

  • Alternative antibodies targeting different epitopes

What factors affect the detection sensitivity of phosphorylated STF1 (pSTF1) in clinical samples?

Detection of phosphorylated transcription factors presents unique challenges:

• Sample handling considerations:

  • Rapid processing is essential as phosphorylation states can change quickly

  • Phosphatase inhibitors must be included in all buffers

  • Standardized cold chain maintenance is critical

• Patient-specific factors affecting detection:

  • Medication status, particularly those affecting signaling pathways

  • Time since last treatment dose

  • Presence of neutralizing antibodies against treatments

  Research findings demonstrate that "Anti interferon-beta (IFN-β) neutralizing antibodies (NAb) affect efficacy of treatment... and exactly when the detrimental effects of NAbs offset therapeutic efficacy is debated" .

• Technical considerations for phospho-STF1 detection:

  • Use phospho-specific antibodies with verified specificity

  • Include both phosphorylated and total protein controls

  • Consider multiplexed detection methods to normalize phospho-signals to total protein

• Analytical approaches for improved sensitivity:

  • Phospho-specific flow cytometry (phosphoflow) allows evaluation of pathway-specific phosphorylation at the single-cell level

  • Principal component analysis (PCA) of phosphorylation data can cluster patients according to treatment response classes

  • Partial least square regression (PLSR) models can predict treatment efficacy

Research has shown that "the best fitting model for [neutralizing antibody] prediction based on PLSR included pStat1 in monocytes, T cells, or lymphocytes and pStat3 in monocytes (r = 0.97)" .

How can I differentiate between different conformational states of proteins using STF1 antibodies in research?

Advanced antibody-based approaches can distinguish between different protein conformational states:

• Conformation-specific antibody selection: Use antibodies that recognize specific protein states. For example, researchers have used antibodies like Y3 that specifically recognize MHC-I proteins when associated with β2m (beta-2-microglobulin) .

• Temperature manipulation: Certain protein conformations can be stabilized at different temperatures. Research has shown that incubating cells at 25°C can stabilize certain protein dimers that would dissociate at 37°C .

• Experimental design for conformational studies:

  • Capture proteins using state-specific antibodies on micropatterns

  • Manipulate conditions (temperature, ligand addition) to induce conformational changes

  • Track changes using fluorescently labeled reagents that bind only to specific conformations

• Quantification approaches:

  • Measure binding of conformation-specific probe molecules

  • Detect co-localization with known interaction partners

  • Analyze FRET signals between labeled domains

• Validation of conformational changes:

  • Correlate with functional readouts

  • Confirm with alternative techniques (e.g., limited proteolysis)

  • Use mutagenesis to stabilize specific conformations

Research has demonstrated that "both Y3 and anti-HA antibodies captured peptide-receptive K^bHC/β2m dimers on the surface of the STF1 cells" , and that these approaches can reveal "conformation-specific protein-protein interactions that require investigation in the native environment of live cells" .

How are STF1 antibodies being integrated with advanced imaging technologies for spatial transcription factor dynamics?

Integration of STF1 antibodies with cutting-edge imaging approaches offers unprecedented insights:

• Super-resolution microscopy applications:

  • STORM (Stochastic Optical Reconstruction Microscopy) combined with STF1 antibodies can reveal nanoscale organization of transcription factor complexes

  • PALM (Photoactivated Localization Microscopy) with photoactivatable fluorophore-conjugated antibodies enables tracking of individual molecules

• Live-cell imaging strategies:

  • Use of antibody fragments (Fab, nanobodies) conjugated to cell-permeable fluorophores

  • Correlation with fluorescently-tagged binding partners

  • Complementation assays for studying protein complex formation in real-time

• Multiplexed imaging approaches:

  • Cyclic immunofluorescence using antibody elution and restaining

  • Mass cytometry imaging (IMC) with metal-labeled antibodies

  • Co-detection by indexing (CODEX) for highly multiplexed protein detection

• Computational analysis of spatial data:

  • Spatial correlation analysis between transcription factors and target genes

  • Clustering analysis to identify transcriptional hubs

  • Tracking of dynamic changes in response to cellular stimuli

What are the considerations for using STF1 antibodies in studying rare cell populations or limited clinical samples?

When working with scarce biological materials:

• Sample preservation strategies:

  • Cryopreservation techniques optimized for small samples

  • Use of fixatives that maintain both morphology and epitope accessibility

  • Development of protocols for sequential or multiplexed analyses from the same sample

• Signal amplification methods:

  • Tyramide signal amplification (TSA) to enhance detection sensitivity

  • Proximity ligation assay (PLA) for detecting protein-protein interactions with high sensitivity

  • Quantum dot-conjugated antibodies for higher signal-to-noise ratio

• Microfluidic approaches:

  • Single-cell analysis platforms requiring minimal sample input

  • Droplet-based assays for high-throughput screening of rare cells

  • Microfluidic Western blotting for protein analysis from limited samples

• Data integration strategies:

  • Correlation of antibody-based detection with transcriptomic data from the same cells

  • Machine learning algorithms to identify patterns in multiparametric data

  • Network analysis to place identified factors in biological context

• Validation approaches for limited samples:

  • Use of patient-derived organoids for functional validation

  • In silico modeling to predict functional outcomes

  • Careful selection of control samples for meaningful comparisons